Insights - Page 2

Our Insights series brings you perspectives on biosimilars from key leaders in the field.
Hope S. Rugo, MD, describes the approval process for biosimilars.
Hope S. Rugo, MD, describes the introduction of the Biologics Price Competition and Innovation Act (BPCIA) to help address concerns about innovation and competition in the market. Cornelius F. Waller, MD, explains how biosimilar products are named.
 
Hope S. Rugo, MD, and Cornelius F. Waller, MD, compare biosimilars with biologics and discuss how they differ from generic products.
 

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2018 Intellisphere, LLC. All Rights Reserved.